Viewing nowCombinationHypoge A Tablet 5/160/10 mg
Amlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.

MFDS item code 202105294 · Approved 2021.07.12 · Insurance code 671706940
Treatment of essential hypertension, improvement of dyslipidemia, and prevention of cardiovascular disease
This medication combines amlodipine and valsartan and is used when blood pressure control in patients with essential hypertension is inadequate. The atorvastatin component helps lower the risk of cardiovascular diseases and treats dyslipidemia. It reduces the risk of myocardial infarction, stroke, need for vascular interventions, and angina in adults with multiple risk factors for cardiovascular disease. It also contributes to the reduction of myocardial infarction and stroke risk in diabetic patients. For patients with existing coronary artery disease, it lowers the risk of hospitalization due to myocardial infarction, stroke, or congestive heart failure and helps manage angina. In dyslipidemia, it is used as an adjunct to dietary therapy to improve cholesterol and triglyceride levels and increase HDL cholesterol levels. This medication is used for the treatment of hypertension, reducing cardiovascular disease risk, and treating dyslipidemia.
Take 1 tablet once daily with water. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medication is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and atorvastatin. For patients taking the amlodipine/valsartan combination and atorvastatin as separate medications, they may be switched to this medication (a combination product containing the same amounts of each active ingredient) for convenience. Before administering the amlodipine/valsartan combination, it is recommended that the dose of each individual component (amlodipine or valsartan) be adjusted. However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. - Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater). However, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. - Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. The amlodipine/valsartan combination should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. - Elderly patients aged 65 years or older: Caution should be exercised when increasing the dose. Patients receiving atorvastatin should follow a standard cholesterol-lowering diet before and during treatment. Atorvastatin may be taken at any time of day, with or without food. 1. Dyslipidemia The recommended initial dose is 10 mg of atorvastatin once daily. However, patients who require a greater reduction in LDL cholesterol may start with 20 mg or 40 mg once daily (only when a reduction in LDL cholesterol of 45 % or more is required). This medication is administered once daily at doses ranging from 10 ~ 80 mg. The initial and maintenance doses of this medication should be individualized according to the patient's characteristics, taking into account the treatment goals and response. Lipid levels should be analyzed within 2 ~ 4 weeks after starting treatment and/or titrating the dose, and the dose should be adjusted accordingly. Because the goal of treatment is to lower LDL cholesterol, it is recommended that LDL cholesterol be used when initiating treatment and evaluating the treatment response. However, if LDL cholesterol levels are unavailable, total cholesterol should be used to monitor the treatment response. Patients with homozygous familial hypercholesterolemia The dose of this medication is 10 ~ 80 mg once daily. It should be administered in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when such treatments are not available. - Patients with renal impairment: No dosage adjustment is necessary because renal disease does not affect the plasma concentration of atorvastatin or its LDL cholesterol-lowering effect. - Elderly patients: The efficacy and safety in elderly patients aged 70 years or older are generally similar to those in the adult patient population.
This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. If muscle problems occur or if muscle enzyme levels rise, treatment with atorvastatin, one of the components of this medication, should be halted. Patients with a known allergy to this medication or specific liver or kidney diseases, as well as pregnant or breastfeeding women, should not take this medication. Patients with sodium or fluid depletion may develop hypotension, so their condition should be carefully monitored before and during treatment, and blood pressure should be closely monitored. Patients with high potassium levels should be cautious when taking potassium-containing supplements or medications with this medication, and potassium levels should be frequently checked. Patients with kidney function issues or those who have received kidney transplants should closely monitor kidney function while taking this medication. If symptoms of angioedema occur, discontinue use immediately and consult a physician; do not take it again. Patients with heart failure or post-myocardial infarction should periodically check kidney function and blood pressure during treatment with this medication. This medication may affect liver function, so it should be taken cautiously in patients with liver disease or abnormal liver function test results. Care should be taken when driving or operating machinery as dizziness or fatigue may occur. Atorvastatin included in this medication may cause side effects such as muscle pain, liver function abnormalities, gastrointestinal symptoms, and headaches. If severe muscle pain or weakness occurs, notify a physician immediately. This medication may interact with other drugs, so patients should inform their physician or pharmacist of any medications currently being taken. This medication is not recommended for pregnant or breastfeeding women, and women of childbearing age should use appropriate contraception.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is recommended to maintain storage temperatures between 1 degree and 30 degrees Celsius. Proper storage will help retain the medication's effectiveness.
Pale yellowish-brown oval film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Amlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
Dongu Bio Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 80mg +1 more
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Valsartan 160mg +1 more
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.